Researchers identified a pathway that begins in the gut and ends with a pro-inflammatory protein in the brain that appears to contribute to the development and progression of Alzheimer's disease.
Fatigue and headaches top the list of common lingering symptoms four months after COVID infection, with muscle aches, changes in sense of taste and smell, cough, and congestion following close behind.
The effects of COVID-19 infection on neurological health are becoming more apparent. A new study reveals COVID-19 can predispose people to irreversible neurological conditions, accelerate brain aging, and increase the risk of stroke and brain bleeds.
A newly developed novel fusion protein drug efficiently eliminates amyloid beta via an entirely different mechanism than amyloid-beta antibody-based immunotherapy.
Microglia that express the Alzheimer's associated APOE4 genetic variant are unable to effectively metabolize lipids. This causes lipids to build up, promoting inflammation and preventing effective neurotransmission.
Study reveals striking similarities in both behaviors and neuroanatomical changes between people with schizophrenia and behavioral-variant frontotemporal dementia.
People given the impression they had control over the music they heard experienced more pain relief than those who felt as though they had no control over their music exposure.
Study questions whether smell loss associated with COVID-19 infection may increase the risk of developing dementia later in life.
Recent scandals in Alzheimer's research and problems with medications designed to help those with Alzheimer's but failing to deliver sufficient results have researchers questioning the overwhelming focus on amyloid-beta in Alzheimer's research.
Those with hereditary hemochromatosis who have two copies of the gene mutation that cause the disorder have an increased risk of developing movement disorders including Parkinson's disease.
Study reveals how somatostatin and copper affect amyloid beta in Alzheimer’s disease pathology.